Clinical efficacy, immunogenicity and safety of RTS,S/AS01, R21/Matrix-M and candidate malaria vaccines in children: A systematic review and meta-analysis.
Katsiaryna Bashlakova, Marianna Zarro, Paolo Villari et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy, immunogenicity, and safety of malaria vaccines in children under 18 years, analyzing 56 trials with 134,424 participants. The overall vaccine efficacy was found to be 31%, with R21-MM showing the highest efficacy at 72%. The study highlights the importance of integrating malaria vaccination into childhood malaria control strategies.
Key findings
- Overall vaccine efficacy was 31% (IRR=0.69; 95% CI 0.57-0.84).
- R21-MM demonstrated a vaccine efficacy of 72% (IRR=0.28; 95% CI 0.22-0.34).
- Serious adverse event rate was 16% overall, with RTS,S/AS02 at 29% and R21-MM at 3%.
- Vaccination combined with seasonal malaria chemoprevention showed 65% efficacy (IRR=0.35; 95% CI 0.23-0.51).
Why it matters
The findings underscore the potential of malaria vaccines to significantly reduce the incidence of clinical malaria in children, which is crucial for public health in endemic regions. Understanding vaccine efficacy and safety profiles can guide vaccination strategies and policy decisions.